Compare BAFN & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | HBIO |
|---|---|---|
| Founded | 1999 | 1901 |
| Country | United States | United States |
| Employees | N/A | 339 |
| Industry | Savings Institutions | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 24.9M |
| IPO Year | 2021 | 2000 |
| Metric | BAFN | HBIO |
|---|---|---|
| Price | $6.25 | $5.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 73.4K | 28.2K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $0.28 |
| 52 Week High | $16.35 | $7.50 |
| Indicator | BAFN | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 51.92 |
| Support Level | $5.94 | $0.47 |
| Resistance Level | $7.08 | $7.25 |
| Average True Range (ATR) | 0.56 | 0.46 |
| MACD | -0.13 | -0.19 |
| Stochastic Oscillator | 16.84 | 38.47 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.